NCT06577415View on ClinicalTrials.gov

A Study of RAY1225 in Participants With Impaired Liver Function

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

November 15, 2025

Conditions

Hepatic Impairment

Interventions

DRUG

RAY1225

Administered SC

Trial Locations (1)

Unknown

RECRUITING

Nanfang Hospital,South Medical Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY